Holen Sie sich die Stockscreener-App
3.8466
4.49%
-0.1634
Schlusskurs vom Vortag:
$4.01
Offen:
$3.96
24-Stunden-Volumen:
41,783
Relative Volume:
0.29
Marktkapitalisierung:
$41.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.25M
KGV:
-2.161
EPS:
-1.78
Netto-Cashflow:
$-17.87M
1W Leistung:
-5.43%
1M Leistung:
-6.81%
6M Leistung:
+8.19%
1J Leistung:
+15.71%
1-Tages-Spanne:
$3.86
$4.00
1-Wochen-Bereich:
$3.75
$4.11
52-Wochen-Spanne:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Firmenname
Lantern Pharma Inc
Sektor
Branche
Telefon
972-277-1136
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Vergleichen Sie LTRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.88 | 43.31M | 0 | -19.25M | -17.87M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.68 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.80 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.80 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
823.31 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.43 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-07 | Eingeleitet | H.C. Wainwright | Buy |
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
Lantern Pharma : Corporate Overview - MarketScreener
How Lantern Pharma Inc. stock performs in weak economyQuarterly Profit Review & Low Risk High Win Rate Stock Picks - newser.com
Can Lantern Pharma Inc. stock deliver consistent earnings growth - newser.com
When is the best time to exit Lantern Pharma Inc.2025 Market Trends & Technical Confirmation Trade Alerts - newser.com
Will Lantern Pharma Inc. stock recover after recent dropEarnings Overview Report & Low Drawdown Trading Techniques - newser.com
How Lantern Pharma Inc. stock reacts to oil pricesWeekly Profit Report & AI Based Buy and Sell Signals - newser.com
What drives Lantern Pharma Inc stock priceEvening Star Patterns & Big Gains Small Budget - earlytimes.in
Is Lantern Pharma Inc. stock attractive for income investorsQuarterly Profit Summary & Short-Term Trading Alerts - newser.com
Using economic indicators to assess Lantern Pharma Inc. potentialJuly 2025 Institutional & Safe Investment Capital Preservation Plans - newser.com
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Pocono Record
Full technical analysis of Lantern Pharma Inc. stock2025 Valuation Update & Weekly Breakout Watchlists - newser.com
Will Lantern Pharma Inc. stock maintain dividend yield2025 Earnings Impact & High Accuracy Investment Signals - newser.com
Lantern Pharma Inc. stock trendline breakdownTrade Volume Summary & Advanced Technical Analysis Signals - newser.com
How to interpret RSI for Lantern Pharma Inc. stockJuly 2025 Momentum & Reliable Intraday Trade Plans - newser.com
Why Lantern Pharma Inc. stock is favored by pension fundsJuly 2025 Opening Moves & Stock Market Timing Techniques - newser.com
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT - MarketScreener
Emerging Biotech Stars Poised for Multi-Billion-Dollar Breakthroughs (MDCX, ACTU, LTRN, TNXP) - MarketScreener
Is Lantern Pharma Inc. stock a buy before product launchesOil Prices & Free Technical Confirmation Trade Alerts - newser.com
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. - BioSpace
Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress - Digital Journal
Lantern Pharma (LTRN) Reports Promising Phase 1 Trial Results fo - GuruFocus
Lantern Pharma presents LP-284 clinical data at 25th LL&M Congress - MarketScreener
What technical signals suggest for Lantern Pharma Inc. stockGDP Growth & Growth Focused Stock Pick Reports - fcp.pa.gov.br
Lantern Pharma’s Promising Phase II Lung Cancer Study: Key Insights for Investors - TipRanks
Lantern Pharma’s LP-284 Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Lantern Pharma’s LP-184 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025 - BioSpace
Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lantern Pharma Inc-Aktie (LTRN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
0.17%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):